Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases

Metastatic Malignant Solid Neoplasm Clinical Trial

Official title:

Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery: A Randomized Phase II Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02387905
• Other study ID #: 2014-0561
• Secondary ID: NCI-2015-0049420
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 9, 2015
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial studies how well cement augmentation works in preventing vertebral body compression fracture following spine stereotactic radiosurgery in patients with solid tumors that have spread to the spine. Spine stereotactic radiosurgery delivers a high dose of radiation to vertebral metastases and can sometimes lead to a vertebral compression fracture. Using body cement on the largest part of the vertebra (a procedure called vertebral body cement augmentation) may help prevent a fracture after stereotactic spinal radiosurgery. It may also lessen pain and improve quality of life in patients with solid tumors and spinal metastases undergoing this surgery.

Description:

PRIMARY OBJECTIVES:

I. To assess whether prophylactic cement augmentation reduces new or progressive vertebral body fracture at 3 months in high risk patients undergoing single fraction spine stereotactic radiosurgery.

SECONDARY OBJECTIVES:

I. To assess the impact of prophylactic cement augmentation on time to first new or progressive vertebral body fracture.

II. To assess the impact of prophylactic cement augmentation on pain control measured every three months post treatment.

III. To assess the impact of prophylactic cement augmentation on quality of life measured every three months post treatment.

IV. To estimate local control in each arm. V. To estimate overall survival in each arm. VI. To document and assess post-treatment adverse side effects between the two arms.

VI. To document and assess the relationship between radiographic vertebral body fracture, pain control and quality of life.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo stereotactic spinal radiosurgery per standard of care.

ARM II: Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 87
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients must have histologic proof of solid tumor malignancy and radiographic evidence of spine metastasis

• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

• Life expectancy of greater than 3 months

• All patients must be able to lie supine

• All patients must have no more than 3 contiguous vertebral body levels treated at a single site, and no more than 3 discontiguous vertebral body levels treated

• All patients must have a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gray (Gy)

• All patients must be deemed at "high risk" of developing vertebral body fracture by having at least one of the following characteristics:

• Spine Instability Neoplastic Score classification of "Indeterminate" deemed as a score from 7 to 12

• Pre-existing vertebral body fracture

• Planned radiation dose of 24 Gy

• All patients must have a vertebral body site to be treated located from T1 to L5

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

• All patients must sign informed consent verifying that they are aware of the investigational nature of this study in keeping with the rules and policies of M.D. Anderson Cancer Center; the only acceptable consent is the one approved by M.D. Anderson Institutional Review Board (IRB)

• Patients undergoing bisphosphonate therapy are allowed

Exclusion Criteria:

• Patients who have had prior radiotherapy at the spine site and level to be treated

• Patients who have had prior surgery at the spine level to be treated to include prior cement augmentation, laminectomy, vertebrectomy, tumor debulking, instrumentation

• Patients with gross disease involving only the posterior elements

• Patients who have > 50% vertebral body collapse

• Patients unable to undergo magnetic resonance imaging (MRI) of the spine

• Patents with cord compression

• Patients deemed not be a candidate for cement augmentation for any reason

• Patients who have frank mechanical pain

• Patients with both pedicles involved with gross disease at the level of potential cement augmentation

• Pregnant women are excluded from this study

• Patients with a histology of lymphoma, myeloma and small cell lung cancer histologies

Related Conditions & MeSH terms

• Fractures, Compression
• Metastatic Malignant Neoplasm in the Spine
• Metastatic Malignant Solid Neoplasm
• Neoplasms

Intervention

Procedure:
• Management of Therapy Complications
Undergo vertebral body cement augmentation

Other:
• Quality-of-Life Assessment
Ancillary studies
• Questionnaire Administration
Ancillary studies

Radiation:
• Stereotactic Radiosurgery
Undergo standard stereotactic spinal radiosurgery

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vertebral compression fracture rate	Will compare the 3-month vertebral compression fracture proportions between treatment groups using the Fisher exact test. Will be performed on the intention-to-treat principle.	At 3 months
Secondary	Time to first new or progressive vertebral body fracture	To assess the impact of prophylactic cement augmentation on time to first new or progressive vertebral body fracture, will use the Kaplan-Meier method to estimate the freedom from fracture curves and Cox proportional hazards regression analysis to estimate the hazard ratio with confidence intervals and associated p-values.	Up to 2 years
Secondary	Pain control, assessed using the Brief Pain Inventory form	Will use mixed effects linear models to analyze this longitudinal data.	Up to 2 years
Secondary	Quality of life, assessed using the MD Anderson Symptom Inventory-Spine Tumor form	Participants are asked to recall symptom severity and interference during the past 24 hours. Part I, The severity of the symptoms, including pain, fatigue, nausea, disturbed sleep, short of breath etc. Part II, How have the symptoms interfered with patient life, including mood, work, relations with other people etc. Part I, range 0-10. A score of 0 would mean the symptom is not present and a score of 10 means the symptom is as bad as you can imagine). Part II, range 0-10 (A score of 0 would mean the symptom did not interfere; A score of 10 means the symptom has interfered completely. The ratings in the MDASI can be averaged into several subscale scores: mean core symptom severity, mean module symptom severity, mean total symptom severity, and mean interference. The interference items can further be broken down into mean activity interference and mean affective interference. Symptom items may be presented individually	Up to 2 years
Secondary	Local control	Will estimate time to first local failure curves using the Kaplan-Meier method.	Up to 2 years
Secondary	Overall survival	Will use the Kaplan-Meier method.	Up to 2 years
Secondary	Incidence of post-treatment adverse events	Will estimate the difference in grade 3+ toxicity rates, with 95% confidence intervals and a chi-squared test p-value.	Up to 2 years
Secondary	Radiographic vertebral body fracture, pain control and quality of life assessment	Will assess the relationship between radiographic vertebral body fracture, pain control and quality of life using correlation analyses. Additional analyses may be conducted as appropriate.	Up to 2 years
Secondary	Quality of life, assessed using the EuroQol 5-dimensional 5-level questionnaire.	Will use mixed effects linear models to analyze this longitudinal data. The questionnaire consists 2 parts.; Part 1 is descriptive system (participants are asked mobility, self-care status, usual activities, pain/discomfort, anxiety/depression, and each dimension has 5 levels; Part 2 is the Visual analogue scale (the self-rated health today with score 0-100; 100 means the best health you can imagine. 0 means the worst health you can imagine) Part 2, participants give self-rated health today with 100 means the best health you can imagine. 0 means the worst health you can imagine. Part 2, higher range represents a better outcome	Up to 2 years

External Links

•   MD Anderson Cancer Center Website